Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma
The phase II L-MIND study demonstrated that treatment with tafasitamab in combination with lenalidomide yielded high complete response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients with primary refractory DLBCL relapsing within three months of frontlin...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2025-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2025.23.174 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!